NCT04192747进行中（未招募）不适用
Evaluation of a Sirolimus Eluting Bioadaptor as Compared to a Zotarolimus Eluting Stent in De Novo Native Coronary Arteries ELX-CL-1805
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 445
- 试验地点
- 36
- 主要终点
- Percentage of Participants With Target Lesion Failure (TLF)
研究概览
简要总结
The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de novo, native coronary artery lesions
详细描述
The Bioadaptor RCT Study is a prospective, 1:1 randomized study of parallel designed, that will enroll up to 444 patients requiring treatment of up to two de novo coronary lesions of ≤ 34 mm in length in vessels of ≥ 2.25 mm and ≤ 4.0 mm in diameter.
One or two designated target lesions, located in separate epicardial vessels (RCA, LCX or LAD), and meeting the inclusion/exclusion criteria may be treated with the ELX1805J (DynamX Bioadaptor) or Resolute Onyx stent
The primary safety endpoint is Target Lesion Failure (TLF) at 12 months. TLF is a composite endpoint defined as cardiac death, target vessel MI, and clinically-indicated target lesion revascularization
Additional secondary safety and effectiveness endpoints will be evaluated at 30 days, 6 and 12 months and 2-5 years.
Using visual assessment, the target lesion must measure ≥ 2.25 mm and ≤ 4.0 mm in diameter and ≤ 34 mm in length able to be covered by a single ELX1805J or Resolute Onyx stent including 2 mm of healthy vessel on either side of the planned treatment area.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria
- •Patients who meet all of the following criteria are eligible:
- •Patient must be ≥ 20 years of age.
- •Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia)
- •Patients who are able to take dual anti-platelet therapy for 1 year following the index procedure and anticoagulants prior to/during the index procedure.
- •The subject is an acceptable candidate for Percutaneous Transluminal Coronary Angioplasty (PTCA), stenting, and emergent Coronary Artery Bypass Graft (CABG) surgery.
- •The subject or subject's legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board or Ethics Committee of the respective clinical site.
- •Women of childbearing potential with a negative pregnancy test within 7 days and women who are not pregnant or nursing
- •Patient must agree to undergo all clinical study required follow up visits, angiograms, and imaging testing
- •Patient must agree not to participate in any other clinical research study for a period of one year following the index procedure
- •Target lesion(s) must be de novo and located in a native coronary artery with a vessel mean diameter of ≥ 2.25 and ≤ 4.0 mm.
- •Target lesion(s) must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and < 100% with a TIMI flow of >
- •When two target lesions are treated, they must be located in separate major epicardial vessels
- •visually estimated target lesion length is ≤ 34mm mm and must be able to be covered by a single 14/15/18/23/28/32/38 mm ELX1805J stent and have at least 2 mm of healthy vessel on either side Or
- •The visually estimated target lesion length is ≤ 34mm mm and must be able to be covered by a single 15/18/22/30/34/38 mm ZES stent respectively and have at least 2 mm of healthy vessel on either side.
- •The lesion(s) must be successfully pre-dilated prior to enrollment Mandatory pre-dilatation includes the use of 2 orthogonal views to confirm lesion inclusion and exclusion criteria and successful pre-dilatation defined as balloon inflation without waist and a lumen diameter no less than 0.5 mm smaller than the vessel diameter.
- •Percutaneous intervention of lesions in a non-target vessel if:
- •Not part of a another clinical investigation
- •≥ 30 days prior to the study index procedure
- •≥ 6 months after the study index procedure (planned)
- •Percutaneous intervention of lesions located in the target vessel if:
- •Not part of a clinical investigation
- •≥ 6 months prior to the study index procedure
- •>12 months after the study index procedure (planned)
- •Previous intervention was distal to and >10 mm from the target lesion
排除标准
- •The patient was diagnosed with an acute myocardial infarction within the past 72 hours and the CK and CKMB have not returned to normal (or cTn >15x ULN) and the patient is experiencing clinical symptoms indicative of ongoing ischemia
- •Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, prasugrel or ticagrelor, cobalt, nickel, chromium, molybdenum, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated
- •Patients with a history of allergic reaction or serious hypersensitivity to drugs exhibiting interactions with sirolimus, zotarolimus, everolimus, tacrolimus, temsirolimus, biolimus and other rapamycin, derivatives or analogues) or similar drugs
- •Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel or other P2Y12 inhibitors.
- •Patient presenting with chronic (permanent) atrial or ventricular arrhythmia or current unstable ventricular arrhythmias
- •Patient has a known left ventricular ejection fraction (LVEF) < 30%
- •Patient has received a heart or other organ transplant or is on a waiting list for any organ transplant
- •Patient has a malignancy that is not in remission.
- •Patient is receiving immunosuppression therapy other than steroids and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)
- •Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that cannot be stopped and restarted according to local hospital standard procedures.
- •Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected to have cirrhosis of Child-Pugh ≥ Class B within 7 days before study procedure
- •Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL within 7 days before study procedure, or patient on dialysis)
- •Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- •Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months
- •Patient has had a significant GI or urinary bleed within the past six months
- •Patient has severe symptomatic heart failure (i.e., NYHA class IV)
- •Patient has a medical condition that precludes safe 6 French sheath insertion
- •Patient has other medical illness or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year)
- •Patient is already participating in another clinical research study which has not reached the primary endpoint (long-term follow-up is not an exclusion)
- •Other patients whom primary investigator or subinvestigator determined to be ineligible for this clinical study
- •Patients with bypass graft to the target vessel or lesion is located in a bypass graft
- •Patients with stent implanted within 10 mm of proximal or distal end of target lesion
- •Patients with a target lesion involving a bifurcation of which the side branch will be jailed by the struts and:
- •Side branch ≥ 2.5 mm in diameter,
- •Side branch requiring predilatation (including Kissing Balloon Technique), or
- •Side branch has an ostial lesion or lesion with > 50% stenosis
- •Patients suspected or confirmed with the QCA analysis of having stenotic lesion of more than 50% in target vessel in addition to target lesion
- •Patients with target lesion in ostia located within 5 mm of origin of LAD, LCX or RCA
- •Patients with stenotic lesion in left main trunk
- •Patients with target lesion that is a chronic total occlusion (CTO) or ≤ TIMI 1 coronary flow in the target vessel
- •Patients with target vessel that contains thrombus as indicated in pre-procedure angiographic, IVUS or OCT images
- •Excessive tortuosity ≥ two 45° angles or extreme angulation (≥ 90°) proximal to or within the target lesion
- •Patients with target vessel that has moderate to severe calcification that prevents complete angioplasty balloon (POBA with non-compliant balloon, or scoring balloon,) inflation or requires other devices such as rotational atherectomy, rotoblator.
- •Patients with dissection of Grade A or B that cannot be covered (including 2mm distal to the dissection) with a single study device or with dissection of Grade C or higher
- •Patients with 2 or more target lesions on 1 branch or target lesions on 3 branches that need to be treated during study procedure
- •Target lesion involves a myocardial bridge
结局指标
主要结局
Percentage of Participants With Target Lesion Failure (TLF)
时间窗: 12 Months
The primary endpoint of the BIOADAPTOR RCT is Target Lesion Failure (TLF), which is a composite endpoint defined as cardiac death, target-vessel MI, and Clinically-Indicated TLR
次要结局
- Percentage of Participants With Target Lesion Failure (TLF)(Through 12 months post-procedure)
- Percentage of Participants With Patient Oriented Clinical Endpoint(Through 12 months)
- Percentage of Participants With Composite of All-cause Mortality(Through 12 months post-procedure)
- Percentage of Participants With Composite of Cardiovascular Death, TVMI and ID-TVR Revascularization(Through 12 months)
- Percentage of Participants With Cardiovascular Death, Stroke, MI and Revascularization(Through 12 months)
- Percentage of Participants With Cardiovascular Death, MI and Revascularization(Through 12 months)
- Percentage of Participants With Clinically Indicated Target Lesion Revascularization (CI-TLR)(Through 12 months post-procedure)
- Percentage of Participants With Target Lesion Revascularization (TLR)(Through 12 months post-procedure)
- Percentage of Participants With Target Vessel Revascularization (TVR)(Through 12 months post-procedure)
- Percentage of Participants With Clinically Indicated TVR (CI-TVR)(Through 12 months post-procedure)
- Percentage of Participants With Revascularization (Target Vessel or Non-target Vessel)(Through 12 months post procedure)
- Percentage of Participants With Q-wave MI(Through 12 months post-procedure)
- Percentage of Participants With Non Q-wave MI(Through 12 months post-procedure)
- Percentage of Participants With MI (Target Vessel or Non-target Vessel)(Through 12 months post procedure)
- Percentage of Participants With Target Vessel MI(Through 12 months post procedure)
- Percentage of Participants With All-cause Mortality(Through 12 months post-procedure)
- Percentage of Participants With Cardiovascular Death(Through 12 months post procedure)
- Percentage of Participants With Composite of Cardiovascular Death or Target Vessel MI(Through 12 months post procedure)
- Percentage of Participants With Composite of All-cause Death or MI(Through 12 months post-procedure)
- Percentage of Participants With Composite of All-cause Death, MI (Target Vessel or Non-target Vessel), or TVR(Through 12 months post-procedure)
- Percentage of Participants With Composite of Probable or Definite Stent Thrombosis(Through 12 months post-procedure)
- Percentage of Participants With Probable Stent Thrombosis(Through 12 months post-procedure)
- Percentage of Participants With Definite Stent Thrombosis(Through 12 months)
研究者
研究点 (36)
Loading locations...
相似试验
已完成
不适用
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery LesionsAtherosclerosis, CoronaryIschemic Heart DiseaseAcute Coronary SyndromeCoronary Artery DiseaseMyocardial IschemiaAngina PectorisNCT02389946Biotronik, Inc.1,334
已完成
不适用
A Safety and Efficacy of Supralimus™ Core™ Sirolimus Eluting Stent at MAX DDHV InstituteCoronary Artery DiseaseNCT00811616Sahajanand Medical Technologies Limited105
已完成
不适用
The All-comers Sirolimus-coated Balloon European RegistryPercutaneous Coronary InterventionAngioplasty, Balloon, CoronaryCoronary Angioplasty, Transluminal BalloonArteriosclerosis, CoronaryNCT03085823Fatebenefratelli and Ophthalmic Hospital2,123
暂停
不适用
Safety and Clinical Performance of a Sirolimus-eluting Absorbable Metal ScaffoldCoronary Artery DiseaseNCT02916485Biotronik AG100
已完成
2 期
A Study of the SMART Stent in the Treatment SFA Disease.Peripheral Artery DiseaseNCT00232869Cordis Corporation93